Phase 2 RCT | Efficacy of Bemarituzumab in patients with FGFR2b-selected gastric or gastro-esophageal junction adenocarcinoma.

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

?Targeting FGFR2b in gastric & gastro-oesophageal junction adenocarcinoma?@TheLancetOncolhttps://t.co/Rc6AGRIf4a
✅FIGHT: FOLFOX6 + plc. vs bemarituzumab
?mPFS: 9.5 vs 7.5 mo, n.s.
?mOS: 19.2 vs 13.5 mo
⛔️eye tox & stomatitis
✅FORTITUDE-101/102 ongoing@myESMO @OncoAlert pic.twitter.com/JTL23o23dY

— Arndt Vogel (@ArndtVogel) October 17, 2022